基础医学与临床 ›› 2010, Vol. 30 ›› Issue (5): 557-560.

• 短篇综述 • 上一篇    

胰腺癌分子靶向治疗的研究进展

厉胜 廖泉 赵玉沛   

  1. 中国医学科学院 北京协和医学院 北京协和医院 中国医学科学院 北京协和医学院 北京协和医院 基本外科 中国医学科学院 北京协和医学院 北京协和医院 基本外科
  • 收稿日期:2009-08-10 修回日期:2010-01-26 出版日期:2010-05-05 发布日期:2010-05-05
  • 通讯作者: 赵玉沛

Progress in molecule-targeted therapy for pancreatic cancer

Sheng LI, Quan LIAO, Yu-pei ZHAO   

  1. PUMC Hospital, CAMS & PUMC Department of General Surgery ,PUMC Hospital ,CAMS & PUMC
  • Received:2009-08-10 Revised:2010-01-26 Online:2010-05-05 Published:2010-05-05
  • Contact: Yu-pei ZHAO

摘要: 胰腺癌是一种恶性度极高的肿瘤,85%的患者在就诊时已丧失手术机会,而常规化疗及放疗等治疗措施的疗效并不理想,因此分子靶向治疗成为近年来胰腺癌研究的热点之一,其中EGFR和VEGF血管内皮生长因子抑制治疗成为研究的重点,临床前期研究已显示出其治疗前景。本文就胰腺癌分子靶向治疗研究的现状做一综述。

关键词: 胰腺癌分子靶向治疗的研究现状

Abstract: Pancreatic cancer is one of the most malignant cancer of all neoplasm. 85% cases are not suitable for surgery when first diagnosed. And the effects of chemotherapy and radiotherapy are not satisfactory. Therefore, molecule-targeted therapy becomes a focus in the research of pancreatic cancer recently. EGFR and VGFR inhibition therapy is the emphasis of this field, and show a great prospect in pre-clinical research. And this article reviews progress in the research of molecule-targeted therapy.

Key words: Progress in the research of molecule-targeted therapy for pancreatic cancer